CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
Atlanta, Georgia, United States and 125 other locations
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...
Phase 1
Atlanta, Georgia, United States and 6 other locations
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Atlanta, Georgia, United States and 33 other locations
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...
Phase 1
Atlanta, Georgia, United States and 13 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Atlanta, Georgia, United States and 36 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Atlanta, Georgia, United States and 73 other locations
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML...
Phase 2
Atlanta, Georgia, United States and 17 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia...
Phase 1
Atlanta, Georgia, United States and 22 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ...
Phase 1
Atlanta, Georgia, United States and 40 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible f...
Phase 3
Atlanta, Georgia, United States and 171 other locations
Clinical trials
Research sites
Resources
Legal